Advanced searches left 3/3

Alpelisib - Springer Nature

Summarized by Plex Scholar
Last Updated: 03 June 2022

* If you want to update the article please login/register

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

"Background Acquired resistance to approved tyrosine kinase inhibitors limits their use in patients with gastrointestinal stromal tumors. This report looked at the safety, tolerability, and efficacy of alisib, a phosphatidylibe inhibitor used in combination with imatinib in patients with advanced GIST who had failed before therapy with both imatinib and sunitinib. These were mixed with 400 mg QD imatinib until a maximum tolerated dose was achieved and/or a dose of alatinib in combination with imatinib was determined. This MTD/RP2D dose was used to determine the clinical effectiveness of this combination in dose growth. Imatinib's MTD was determined as 350 mg QD by the MTD. After oral administration in patients with advanced GIST, the MTD of alluded is estimated as 350 mg QD when used in combination with imatinib 400 mg QD.

Source link: https://doi.org/10.1186/s12885-022-09610-4

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions